http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2578811-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1558a05d75a1458a9fbcab80e7a0b0ad |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M5-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B17-03 |
| filingDate | 2015-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13709758e3778415e4ae5de9f91d89b1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e787de1d1a592b545a5486707735a2d1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7db1f83d503e5bc384cdab2c4396903a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7db5b3af1513a870fb9d6a8fe0de2823 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec3d0ea0dd07122eece54cea1c1c17ab |
| publicationDate | 2016-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2578811-C1 |
| titleOfInvention | Method for prevention of infectious-inflammatory complications of transanal endoscopic resection of rectum for tumours |
| abstract | FIELD: medicine. n SUBSTANCE: invention can be used for prevention of infectious-inflammatory complications during transanal endoscopic resection of rectum apropos benign and malignant tumours. For this purpose during transanal endoscopic resection of rectum under the condition of intestinal content ingress into the mezorectal cellular tissue, presence of inflammatory changes of the rectal wall in the area of the tumour, the mezorectal cellular tissue is infiltrated with 20 ml of ozonised physiologic saline in the amount of 1000 mcg/l. Then a preparation of interferon alpha 1 is introduced into the mezorectal cellular tissue in the amount of 1 million IU. After that, mezorectal cellular tissue is sprayed with 1 gram of metronidazole powder. Then, at the following stage, the rectal wall is closed in a standard way. n EFFECT: simple to implement method enables to individualise the therapeutic approach when predicting a high risk of development of infectious-inflammatory complications, ensuring a reduced rate of complications development and of the rate of rectum rhaphes lack. n 1 cl, 2 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2678642-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2709831-C1 |
| priorityDate | 2015-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 41.